| Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. | |
| | |
MedLine Citation:
|
PMID: 20541444 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The novel analgesic tapentadol combines mu-opioid receptor agonism and noradrenaline reuptake inhibition in a single molecule and shows potent analgesia in various rodent models of pain. We analyzed the contribution of opioid and monoaminergic mechanisms to the activity of tapentadol in rat models of nociceptive and neuropathic pain. Antinociceptive efficacy was inferred from tail withdrawal latencies of experimentally naive rats using a tail flick test. Antihypersensitive efficacy was inferred from ipsilateral paw withdrawal thresholds toward an electronic von Frey filament in a spinal nerve ligation model of mononeuropathic pain. Dose-response curves of tapentadol (intravenous) were determined in combination with vehicle or a fixed dose (intraperitoneal) of the mu-opioid receptor antagonist naloxone (1mg/kg), the alpha2-adrenoceptor antagonist yohimbine (2.15 mg/kg), or the serotonin 5-HT(2A) receptor antagonist ritanserin (0.316 mg/kg). Tapentadol showed clear antinociceptive and antihypersensitive effects (>90% efficacy) with median effective dose (ED(50)) values of 3.3 and 1.9 mg/kg, respectively. While the antinociceptive ED(50) value of tapentadol was shifted to the right 6.4-fold by naloxone (21.2mg/kg) and only 1.7-fold by yohimbine (5.6 mg/kg), the antihypersensitive ED(50) value was shifted to the right 4.7-fold by yohimbine (8.9 mg/kg) and only 2.7-fold by naloxone (5.2mg/kg). Ritanserin did not affect antinociceptive or antihypersensitive ED(50) values of tapentadol. Activation of both mu-opioid receptors and alpha2-adrenoceptors contribute to the analgesic effects of tapentadol. The relative contribution is, however, dependent on the particular pain indication, as mu-opioid receptor agonism predominantly mediates tapentadol's antinociceptive effects, whereas noradrenaline reuptake inhibition predominantly mediates its antihypersensitive effects. |
| | |
Authors:
|
Wolfgang Schröder; Jean De Vry; Thomas M Tzschentke; Ulrich Jahnel; Thomas Christoph |
Related Documents
:
|
9766834 - Sex differences in opioid and n-methyl-d-aspartate mediated non-opioid biting fly expos... 10218804 - Activation and internalization of the mu-opioid receptor by the newly discovered endoge... 14718254 - Dual effects of intrathecal bam22 on nociceptive responses in acute and persistent pain... 10209244 - Growth inhibitory effects of a mu opioid on cultured cholinergic neurons from fetal rat... 7251944 - Freeze-fracture study of the crayfish stretch receptor. 3257584 - Signal transduction through the egf receptor transfected in il-3-dependent hematopoieti... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2010-06-11 |
Journal Detail:
|
Title: European journal of pain (London, England) Volume: 14 ISSN: 1532-2149 ISO Abbreviation: Eur J Pain Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-23 Completed Date: 2010-12-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9801774 Medline TA: Eur J Pain Country: England |
Other Details:
|
Languages: eng Pagination: 814-21 Citation Subset: IM |
Copyright Information:
|
Copyright 2010 European Federation of International Association for the Study of Pain Chapters. Published by Elsevier Ltd. All rights reserved. |
Affiliation:
|
Grünenthal GmbH, Global Preclinical Research and Development, Department of Pharmacology, Aachen, Germany. wolfgang.schroeder@grunenthal.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic alpha-2 Receptor Antagonists
/
pharmacology Analgesics, Opioid / pharmacology, therapeutic use Analysis of Variance Animals Dose-Response Relationship, Drug Linear Models Male Naloxone / pharmacology Narcotic Antagonists / pharmacology Neuralgia / drug therapy*, metabolism* Norepinephrine / metabolism* Pain Measurement / drug effects Phenols / pharmacology, therapeutic use* Rats Rats, Sprague-Dawley Receptors, Opioid, mu / agonists* Yohimbine / pharmacology |
| Chemical | |
Reg. No./Substance:
|
0/3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol; 0/Adrenergic alpha-2 Receptor Antagonists; 0/Analgesics, Opioid; 0/Narcotic Antagonists; 0/Phenols; 0/Receptors, Opioid, mu; 146-48-5/Yohimbine; 465-65-6/Naloxone; 51-41-2/Norepinephrine |
| Comments/Corrections | |
Comment In:
|
Eur J Pain. 2010 Sep;14(8):781-3
[PMID:
20659810
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Transition of adolescents with HIV to adult care: characteristics and current practices of the adole...
Next Document: Continuous flow Overhauser dynamic nuclear polarization of water in the fringe field of a clinical m...